Research groups eyes up clinical trials.
The study will examine the safety of ICVT when used to treat Adenovirus Keratoconjunctivitis. Henderson yesterdaysaid it was informed by its development partner Croma Pharma that all six trial centres in Austria and Slovakia had received the necessary ethics committee approval and that stocks of the treatment had been delivered.
Treatment of the first patients, who were enrolled during January, has now started.
Dr Andreas Clausen, head of the clinical project team for the ICVTA12 trial, said: 'The start of this clinical trial means that our aim of producing a safe and effective therapy for Adenoviral Keratoconjunctivitis has taken a step forward.'
|Printer friendly Cite/link Email Feedback|
|Publication:||The Birmingham Post (England)|
|Date:||Feb 10, 2004|
|Previous Article:||Record land deals for property consultancy.|
|Next Article:||Cerro's press first in the UK; Italian engineering: Technology key to cost-effective production.|